Cargando…
Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience
INTRODUCTION: Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed first-line chemotherapy and has been approved for use in patients with LPS in the USA and Europe due...
Autores principales: | Steinbrecher, Oskar, Brodowicz, Thomas, Raderer, Markus, Scharrer, Anke, Fabsits, Johannes, Lamm, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932822/ https://www.ncbi.nlm.nih.gov/pubmed/36273457 http://dx.doi.org/10.1159/000527632 |
Ejemplares similares
-
Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma
por: Lamm, W., et al.
Publicado: (2010) -
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023) -
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022) -
Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?
por: Rastogi, Sameer, et al.
Publicado: (2017) -
Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
por: Tamiya, Hironari, et al.
Publicado: (2020)